A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy
Open Access
- 12 May 2011
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 64 (3), 210-217
- https://doi.org/10.1016/j.phrs.2011.05.003
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Effects of rituximab in two patients with dysferlin-deficient muscular dystrophyBMC Musculoskeletal Disorders, 2010
- Co‐administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humansBritish Journal of Pharmacology, 2010
- The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the NetherlandsPharmacological Research, 2010
- Nitric oxide: A short lived molecule stays alivePharmacological Research, 2010
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic miceCardiovascular Research, 2010
- MALDI reveals membrane lipid profile reversion in MDX miceNeurobiology of Disease, 2009
- NCX 2057, a novel NO‐releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo modelsBritish Journal of Pharmacology, 2009
- Nitric oxide and repair of skeletal muscle injuryNitric Oxide, 2009
- Development of a Nitric Oxide-Releasing Analogue of the Muscle Relaxant Guaifenesin for Skeletal Muscle Satellite Cell MyogenesisMolecular Pharmaceutics, 2009
- Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophyThe FASEB Journal, 2009